12/04/2019

Fidia Announces Expansion into the US Dietary Supplement Market with Launch of CartiJoint™ FORTE

Fidia Farmaceutici is introducing CartiJoint™ FORTE, its first product in the dietary supplement category in the USA, through its wholly-owned subsidiary based in the U.S., Fidia Pharma USA Inc.

CartiJoint™ FORTE is a dietary supplement that supports joint health and mobility with antioxidant activity in a daily dose. It is uniquely formulated with a bioactive curcumin extract Bio-Curcumin Curcugreen™ which is 100% natural turmeric along with glucosamine hydrochloride and chondroitin sulfate.

The introduction of CartiJoint™ FORTE reinforces Fidia’s growth in the U.S., by diversifying into new, emerging product categories that are in line with the company mission of innovating and pioneering new treatment options that will benefit patients, as well as healthcare providers.
 

Unique formulation with a bioactive curcumin extract Bio-Curcumin Curcugreen™ (100% natural turmeric), glucosamine hydrochloride and chondroitin sulfate.

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Fidia’s other websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Middle East product portfolio focalizes primarily on therapeutic areas such as joint healthcare and tissue repair.

Fidia Pharma Middle East is focused on providing consumers with innovative products that offer quality, safety and performance and exploring innovative channel strategies to access customers and consumers, such as healthcare e-commerce.